- Martin Shkreli, 32, founder and chief executive of Turing Pharmaceuticals, purchased the rights to Daraprim in August for $55million
- He raised the price of the drug form $13.50 per tablet to $750 per tablet
- Shkreli has backed the decision, saying that his company 'need to turn a profit on the drug'
- Daraprim treats toxoplasmois, an opportunistic parasitic infection that can cause serious and life-threatening problems
21 September 2015
UK DAILY MAIL: SWISS firm TURING PHARM AB bought Marketing Rights to DARAPRIM (PYRIMETHAMINE)
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment